Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Bausch & Lomb: Firm's revenues expected to grow in mid-single digits in FY 2004 based on continued strong sales from contact lens, lens care, pharmaceuticals categories, CEO Frank Zarrella projects during Oct. 30 earnings call. For the third quarter ended Sept. 27, B&L records 7.5% increase in lens care sales to $131.2 mil. as the ReNu brand continued to post impressive gains. Overall third quarter sales rose 9% to $508.8 mil.; net earnings totaled $32.3 mil. versus $9.4 mil. last year...
You may also be interested in...
Ester-E launch
Enhanced supplement Ester-E will begin rolling out in late spring 2004, Zila announces. The promotional campaign will begin at launch with national radio ads featuring spokesperson Larry King, and expand to television and print later in the year. A clinical trial measuring cardiovascular health as the primary endpoint is set to commence in May. Zila's Ester-E technology is based on a patented process for manufacturing tocopherol phosphate, obtained from Australia-based Vital Health Sciences. Zila recorded a 36% revenue increase on the strength of Ester-C sales in the fourth quarter ended July 31 (1"The Tan Sheet" Nov. 3, 2003, p. 15)...
Ester-E launch
Enhanced supplement Ester-E will begin rolling out in late spring 2004, Zila announces. The promotional campaign will begin at launch with national radio ads featuring spokesperson Larry King, and expand to television and print later in the year. A clinical trial measuring cardiovascular health as the primary endpoint is set to commence in May. Zila's Ester-E technology is based on a patented process for manufacturing tocopherol phosphate, obtained from Australia-based Vital Health Sciences. Zila recorded a 36% revenue increase on the strength of Ester-C sales in the fourth quarter ended July 31 (1"The Tan Sheet" Nov. 3, 2003, p. 15)...
Ester-E launch
Enhanced supplement Ester-E will begin rolling out in late spring 2004, Zila announces. The promotional campaign will begin at launch with national radio ads featuring spokesperson Larry King, and expand to television and print later in the year. A clinical trial measuring cardiovascular health as the primary endpoint is set to commence in May. Zila's Ester-E technology is based on a patented process for manufacturing tocopherol phosphate, obtained from Australia-based Vital Health Sciences. Zila recorded a 36% revenue increase on the strength of Ester-C sales in the fourth quarter ended July 31 (1"The Tan Sheet" Nov. 3, 2003, p. 15)...